10x Genomics, Inc. — Director's Dealing 2024

Dec 24, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: 10x Genomics, Inc. (TXG)
CIK: 0001770787
Period of Report: 2024-12-23

Reporting Person: Saxonov Serge (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-12-23	Class A Common Stock	M	12000	$1.2	Acquired	884574	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-12-23	Stock Option (right to buy)	$1.2	M	12000	Disposed	2027-10-18	Class A Common Stock (12000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Class A Common Stock	27	Indirect
Class A Common Stock	870	Indirect
Class A Common Stock	213250	Indirect
Class A Common Stock	22570	Indirect

Footnotes

F1: The shares are held by the Andromeda Trust, for which the Reporting Person serves as trustee.

F2: The shares are held by the Sirius Trust, for which the Reporting Person serves as trustee.

F3: The shares are held by the Y/S Descendants' Trust, for which the Reporting Person serves as trustee.

F4: The shares are held by the Y/S Pot Trust, for which the Reporting Person serves as trustee.

F5: This option, originally for 300,000 shares, of which 232,537 have been exercised, vested as to 1/48th of the shares on October 1, 2017, and was fully vested as of October 1, 2021.